ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• Analysts maintain a “Moderate Buy” consensus on ARS Pharmaceuticals, with four buys, one hold and one sell among six firms. The average 12-month price target is $28.20.
• ARS Pharmaceuticals faces securities class-action litigation related to investor purchases between March 9 and June 24, 2026; the lead-plaintiff deadline is October 5, 2026. The announcements create near-term headline risk but do not establish liability or potential damages.
• The company remains financially unprofitable: quarterly EPS of negative $0.61 missed estimates, despite revenue of $22.68 million exceeding forecasts. Shares opened at $5.95, near the lower end of their 52-week range, while insiders recently sold shares under pre-arranged trading plans.

Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) have received an average rating of "Moderate Buy" from the six ratings firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $28.20.

Several research firms recently commented on SPRY. Weiss Ratings upgraded ARS Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Monday, June 1st. Leerink Partners decreased their price objective on ARS Pharmaceuticals from $25.00 to $24.00 and set an "outperform" rating on the stock in a research report on Thursday, June 25th. Cantor Fitzgerald raised their price objective on ARS Pharmaceuticals from $12.00 to $30.00 and gave the company an "overweight" rating in a research note on Thursday, May 28th. Finally, Wall Street Zen upgraded ARS Pharmaceuticals from a "strong sell" rating to a "sell" rating in a report on Saturday, May 16th.

Insider Buying and Selling at ARS Pharmaceuticals

In related news, insider Alexander A. Fitzpatrick sold 3,355 shares of the firm's stock in a transaction on Friday, June 12th. The stock was sold at an average price of $10.00, for a total value of $33,550.00. Following the completion of the sale, the insider directly owned 90,910 shares in the company, valued at $909,100. This trade represents a 3.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Eric Karas sold 25,000 shares of the business's stock in a transaction on Friday, June 12th. The shares were sold at an average price of $10.00, for a total transaction of $250,000.00. Following the transaction, the insider owned 12,176 shares in the company, valued at $121,760. This trade represents a 67.25% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 33.80% of the company's stock.

Hedge Funds Weigh In On ARS Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Torren Management LLC bought a new stake in ARS Pharmaceuticals in the fourth quarter worth about $32,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of ARS Pharmaceuticals by 25.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,803 shares of the company's stock valued at $56,000 after buying an additional 982 shares during the period. Bessemer Group Inc. grew its stake in shares of ARS Pharmaceuticals by 3,102.1% during the first quarter. Bessemer Group Inc. now owns 7,525 shares of the company's stock valued at $61,000 after buying an additional 7,290 shares during the last quarter. Osterweis Capital Management Inc. bought a new position in shares of ARS Pharmaceuticals during the fourth quarter valued at approximately $65,000. Finally, Russell Investments Group Ltd. raised its holdings in shares of ARS Pharmaceuticals by 197.5% in the third quarter. Russell Investments Group Ltd. now owns 6,668 shares of the company's stock worth $67,000 after buying an additional 4,427 shares during the period. 68.16% of the stock is currently owned by institutional investors.

Trending Headlines about ARS Pharmaceuticals

Here are the key news stories impacting ARS Pharmaceuticals this week:

• Negative Sentiment: Multiple firms, including Pomerantz, Rosen, Bronstein Gewirtz & Grossman, Kaplan Fox, and others, said a securities class action has been filed on behalf of investors who purchased ARS Pharmaceuticals securities between March 9 and June 24, 2026. The suit alleges violations of federal securities laws, although the notices do not provide detailed findings or establish liability. Pomerantz investor alert
• Negative Sentiment: Investors affected during the class period were repeatedly encouraged to contact law firms about seeking lead-plaintiff status. The stated deadline to petition for appointment as lead plaintiff is October 5, 2026, keeping the litigation in the market’s focus in the near term. Faruqi shareholder action reminder
• Neutral Sentiment: The numerous announcements largely repeat the same lawsuit and deadline information rather than reporting a new operating or regulatory development. Their volume may amplify headline risk, but the notices alone do not determine the lawsuit’s outcome or quantify potential damages.

ARS Pharmaceuticals Price Performance

ARS Pharmaceuticals stock opened at $5.95 on Wednesday. ARS Pharmaceuticals has a 52-week low of $4.91 and a 52-week high of $17.46. The company has a quick ratio of 4.77, a current ratio of 4.94 and a debt-to-equity ratio of 2.79. The firm's fifty day moving average is $7.75 and its 200 day moving average is $8.39. The company has a market cap of $590.84 million, a price-to-earnings ratio of -2.96 and a beta of 0.98.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.61) EPS for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.08). The business had revenue of $22.68 million during the quarter, compared to analysts' expectations of $22.20 million. ARS Pharmaceuticals had a negative return on equity of 153.61% and a negative net margin of 200.00%. Sell-side analysts forecast that ARS Pharmaceuticals will post -1.95 EPS for the current fiscal year.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source